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Statins are potent cholesterol-lowering drugs that can have serious adverse effects on the muscles and 
liver. The aim of our in vitro study was to establish the protective effect of coenzyme Q10 (CoQ10, in its 
optimal dose of 200 µmol L-1) against cytotoxicity induced by atorvastatin, simvastatin, and lovastatin in 
isolated rat hepatocytes by observing parameters such as cell death, reactive oxygen species formation, 
lipid peroxidation, mitochondrial membrane potential, and cellular reduced and oxidised glutathione 
content. Our findings have shown that pretreatment with CoQ10 was effective in reducing the toxic effects 
of statins in rat hepatocytes. This work demonstrates that the addition of CoQ10 to statin treatment regimens 
may protect hepatocytes (and also other types of cells) from statin-induced injuries and alleviate their side 
effects.
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While the effects of statins in reducing the risk of 
cardiovascular disease are well established, less is 
known about their risks, side effects (1), and toxicity 
(2–5).
Coenzyme Q10 (CoQ10), also known as ubiquinone, 
is a potent antioxidant, membrane stabiliser (6), and 
an integral cofactor in the mitochondrial respiratory 
chain (7) that helps to generate adenosine triphosphate 
(ATP) (8). It may also regulate genes associated with 
cell metabolism (9, 10), and its depletion may have a 
role in statin-induced myalgia (11, 12).
In several clinical studies Q10 was supplemented 
to statins to see whether Q10 would decrease statin-
induced side effects (10, 13, 14). These studies were 
small and underpowered, and have found no protective 
effect of Q10 supplementation.
Based on our earlier in vitro finding (4) of statin 
hepatotoxicity through reactive oxygen species (ROS) 
formation and consequent oxidative stress and on the 
evidence of reduced oxidative stress in hepatocytes 
treated with different antioxidants (15), this study 
aimed to establish the protective role of CoQ10 against 
statin toxicity in rat hepatocytes by observing its 
effects on parameters such as ROS formation, lipid 
peroxidation (LPO), mitochondrial membrane 
potential, cellular reduced and oxidised glutathione 
(GSH/GSSG), and cell viability. Our secondary aim 




Atorvastatin, simvastatin, lovastatin, CoQ10, 
rhodamine 123, 5,5′-dithio-bis (2-nitro-benzoic acid) 
(DTNB), 2’,7’-dichlorofluorescin diacetate (DCF), 
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glutathione reductase from baker ’s  yeast , 
β-nicotinamide adenine dinucleotide (NADPH), and 
collagenase from Clostridium histolyticum were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic 
acid (HEPES), 2-vinylpyridine, triethanolamine, and 
oxidised glutathione (GSSG) were obtained from 
Acros (New Jersey, NJ, USA). Bovine serum albumin 
was purchased from Roche Diagnostics (Indianapolis, 
IN, USA). Ethyleneglycol-bis(ρ-aminoethyl ether)-
N,N,N′,N′-tetraacetic acid (EGTA), N-methylthiourea, 
trichloroacetic acid (TCA), and trypan blue were 
obtained from Merck (Darmstadt, Germany). 
Thiobarbituric acid was obtained from SERVA 
(Heidelberg, Germany). All salts used for preparing 
buffer solutions were of analytical grade and obtained 
from Merck.
Hepatocyte isolation
Hepatocytes were isolated from 18 male Sprague-
Dawley rats (weighing 250–300 g) raised at Tabriz 
University of Medical Sciences, Tabriz, Iran, caged 
in standard conditions (temperature 21–23 °C, relative 
humidity 50–60 %) and fed on standard chow diet 
with free access to water. The animals were handled 
and used according to the animal handling protocol 
of Tabriz University of Medical Sciences, approved 
by a local ethics committee.
The procedure involved two-step collagenase 
perfusion as described by Moldeus et al. (16). About 
85–90 % of hepatocytes were viable at the time of 
isolation, as established by the trypan blue uptake test 
(17). Viable cells were suspended in Krebs-Henseleit 
buffer (1x106 cells mL-1) containing 12.5 mmol L-1 of 
HEPES and incubated under a stream of carbogen gas 
(95 % O2 and 5 % CO2) in continuously rotating round-
bottomed 50 mL flasks at 37 °C. Hepatocytes were 
kept under these conditions for 30 min to achieve 
equilibrium between the gas and liquid phases before 
the addition of chemicals.
Cell viability and treatment doses
The viability of cells treated with atorvastatin, 
simvastatin, lovastatin, and CoQ10 was assessed using 
the trypan blue (0.1 %, w/v) uptake test described 
elsewhere (17) at incubation hour one, two, and three. 
For this test, atorvastatin, simvastatin and/or CoQ10 
were dissolved in methanol and lovastatin in dimethyl 
sulphoxide. The maximum volume of the solvent was 
20 µL. In the absence of statins, none of the solvents 
affected hepatocyte viability at the concentrations 
used.
As described elsewhere (4), LC50 was a drug 
concentration which caused 50 % cell death after 
120 min of incubation. For atorvastatin it was 
450 µmol L-1, for simvastatin 200 µmol L-1, and for 
lovastatin 200 µmol L-1.
By trying out different doses of CoQ10, we found 
that the optimum effective dose of CoQ10 was 
200 µmol L-1. We then experimented with treatment 
times by adding this optimal CoQ10 dose 30 min before 
statins, at the same time with statins, and 30 min after 
statins. The most effective timing was 30 min before 
statins (data not shown). In other words, all further 
experiments in this study were carried out with 
200 µmol L-1 of CoQ10 added 30 min before statins. 
These concentrations are much higher than those 
found in serum during statin treatment which is in the 
range of 1–10 nmol L-1 (18).
We used the accelerated cytotoxicity mechanism 
screening (ACMS) technique with freshly isolated rat 
hepatocytes to explore the mechanisms of statin-
induced toxicity and possible protective effects of 
CoQ10. This technique is useful and important in 
determining the cytotoxic effectiveness of a drug or 
xenobiotic in a freshly isolated rat hepatocyte 
suspension over two to three hours. A major advantage 
of ACMS is that a high drug dose over these two to 
three hours exhibits the same hepatotoxicity in vitro 
as would a lower drug dose over a longer period of 
time (24 to 48 h) exhibit in vivo (19, 20). In other 
words, this method can be used to characterise and 
predict hepatotoxicity in vivo.
ROS formation
ROS formation was measured as described earlier 
(21). In short, we added 1.6 µmol L-1 of DCF to 
hepatocytes incubated with statins, where it hydrolysed 
to non-fluorescent dichlorofluorescein (DCFH) and 
then reacted with ROS to form highly fluorescent 
DCFH. Fluorescence intensity was measured in 1 mL 
of hepatocyte suspension (106 cells) using a Jasco® 
FP-750 spectrofluorometer (Jasco Corporation, Tokyo, 
Japan) at excitation and emission wavelengths of 500 
and 520 nm, respectively.
LPO assay
Lipid peroxidation was determined using the 
thiobarbituric acid reactive substances (TBARS) 
assay, which measures aldehydes formed by 
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degradation of lipid hydroperoxides. Absorbance was 
recorded by a Pharmacia Biotech Ultrospec® 2000 
spectrophotometer (Cambridge, UK) at 532 nm after 
treating 1.0 mL aliquots of hepatocyte suspension (106 
cells mL-1) with trichloroacetic acid (70 %, w/v) and 
boiling the supernatant with thiobarbituric acid (0.8 %, 
w/v) for 20 min (22).
Cellular GSH/GSSG
Reduced and oxidised glutathione (GSH and 
GSSG) hepatocyte levels were determined using the 
enzymatic recycling method (23). To determine GSH, 
we took 1 mL aliquots of suspended cells (106 
cells mL-1) and centrifuged them with 2 mL of 5 % 
trichloroacetic acid. Then we added 0.5 mL of 
Ellman’s reagent (0.0198 % DTNB in 1 % sodium 
citrate) and 3 mL of phosphate buffer (pH 8.0). The 
absorbance of developed colour was determined at 
412 nm using a Biotech Pharmacia Ultrospec® 2000 
spectrophotometer.
To assess hepatocyte GSSG levels, we first bonded 
cellular GSH with 2-vinylpyridine and then neutralised 
the excess of 2-vinylpyridine with thriethanolamine. 
GSSG was then reduced to GSH with glutathione 
reductase and NADPH. The amount of GSH formed 
in this way was measured as described above (23).
Mitochondrial membrane potential assay
Mitochondrial membrane potential (MMP) was 
assessed by monitoring the uptake of rhodamine 123, 
as described elsewhere (24, 25). Isolated cells were 
extracted and then resuspended in their original media 
containing 1.5 µmol L-1 of rhodamine 123. After 
10 min of incubation, the cells were centrifuged and 
supernatant absorption measured with a Jasco® FP-750 
spectrofluorometer. The amount of dye remaining in 
the supernatant was inversely proportional to MMP. 
The results are reported as the difference in fluorescence 
intensity between control and treated cells and 
expressed as percentage of control.
Statistical analysis
The chi-square test was used for cell viability, 
cellular GSH, and MMP. One-way analysis of 
variance, followed by Tukey’s post-hoc test, was used 
for LPO and ROS formation. A p-value of <0.05 was 
considered significant.
RESULTS
Results are shown as mean±standard error (SE) of 
marker measurements from at least three separate 
experiments. The cell viability test (with trypan blue) 
showed that atorvastatin, simvastatin, and lovastatin 
were toxic to hepatocytes in a time-dependent manner 
(Table 1). The most toxic was simvastatin, but CoQ10 
effectively reduced cell death induced by all the 
statins. Statins significantly depleted cellular 
glutathione reservoirs (Figure 1) and increased the 
levels of oxidised glutathione (Figure 2), which is an 
indicator of oxidative stress (22). Thirty-minute 
pretreatment of hepatocytes with CoQ10 significantly 
lowered GSSG and increased GSH levels (Figure 1 
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Table 1 Protective effect of pretreatment with CoQ10 against statin-induced cytotoxicity in isolated rat hepatocytes expressed 
as percentage of trypan blue uptake (mean±SD) 
Treatment
Incubation time / min
60 120 180
Control 18±1 22±1 24±1
CoQ10 200 µmol L
-1 15±1 17±1 19±2
Atorvastatin 450 µmol L-1 36±1a 52±2a 68±1a
+ CoQ10 200 µmol L
-1 28±1 35±2b 49±2b
Simvastatin 200 µmol L-1 38±2a 54±2a 88±2a
+ CoQ10 200 µmol L
-1 34±3 41±4b 59±3b
Lovastatin 200 µmol L-1 39±2a 52±2a 74±5a
+ CoQ10 200 µmol L
-1 30±3 37±2b 53±5b
a Significantly different from control (n=3, chi-square, p<0.05); b Significantly different from statin-treated group (n=3, chi-
square, p<0.05) 
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Figure 1 Statin-induced GSH depletion in isolated rat 
hepatocytes and the protective effect of CoQ10
a: significantly different from control (n=3, chi-square, 
p<0.05); b: significantly different from the statin-treated group 
(n=3, chi-square, p<0.05) 
and Figure 2). Similarly, statins significantly increased 
ROS formation, and CoQ10 pretreatment effectively 
attenuated the process (Figure 3). The same is true for 
LPO (Figure 4), confirming earlier findings (26). 
Statins also decreased MMP in respect to control cells, 
while CoQ10 (200 µmol L
-1) pretreatment effectively 
countered their effects (Figure 5).
DISCUSSION
Our study has confirmed the beneficial, 
cytoprotective effects of CoQ10 against statin-induced 
oxidative stress, as it significantly improved all the 
investigated parameters. We already know that CoQ10 
participates in the electron transport chain in 
mitochondria (27) and that statins can interfere with 
CoQ10, compromising cellular energy production (28). 
La Guardia et al. (29) have demonstrated that 
simvastatin inhibits mitochondrial respiration, 
depletes CoQ10, and increases hydrogen peroxide 
production. A small increase in CoQ10 concentration 
in mitochondrial membranes can therefore restore 
mitochondrial respiration (7) as one of the mechanisms 
to protect liver cells from statin toxicity.
The second fundamental property of CoQ10 
involves its antioxidative (free radical scavenging) 
function (30, 31). The efficacy of CoQ10 treatment 
against mitochondrial dysfunction induced by beta 
Figure 2 Statin-induced GSSG elevation in isolated rat 
hepatocytes and the protective effect of CoQ10
a: significantly different from control (n=3, chi-square, p<0.05); 
b: significantly different from the statin-treated group (n=3, chi-
square, p<0.05)
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Figure 3 Statin-induced ROS formation in isolated rat 
hepatocytes and the protective effect of CoQ10
a: significantly different from control (n=3, ANOVA, p<0.05); 
b: significantly different from the statin-treated group (n=3, 
ANOVA, p<0.05)
amyloid has been evaluated in the brains of diabetic 
rats, where CoQ10 treatment attenuated the decrease 
in oxidative phosphorylation and prevented increased 
hydrogen peroxide production (32). This effect, in 
addition to its role in mitochondria, may be due to the 
ability of CoQ10 to scavenge free radicals and reactive 
metabolites produced during statin metabolism, which 
is also supported by lower ROS formation, MMP, 
LPO, and GSH oxidation in our experiments.
Ali et al. (33) have shown that L-carnitine and 
CoQ10 have a pronounced prophylactic effect against 
liver damage induced by halogenated alkanes such as 
carbon tetrachloride (CCl4). In that study, the 
investigators pretreated rats with CoQ10 24 h before 
the administration of CCl4. This is in accordance with 
our finding that the best protection was achieved with 
CoQ10 pretreatment. Most toxins start by affecting the 
cytoplasm. However, the major site of action for CoQ10 
is the mitochondrion, where it is needed for electron 
transfer in mitochondrial respiration. If CoQ10 is 
consumed in the cytoplasm as an antioxidant, it will 
fall short of its role in the mitochondrial respiratory 
chain. However, if CoQ10 abounds in the mitochondria 
before toxic effects take place, it will be able to 
counteract both the reactive metabolites in the 
cytoplasm and ROS produced in the mitochondria.
Figure 4 Statin-induced lipid peroxidation in isolated rat 
hepatocytes and the protective effect of CoQ10
a: significantly different from control (n=3, ANOVA, p<0.05); 
b: significantly different from the statin-treated group (n=3, 
ANOVA, p<0.05)
TBARS-thiobarbituric acid reactive substances
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While the ACMS method we used in our in vitro 
experiments may have minor limitations related to 
short incubation time (34), it simulates in vivo effects 
of statins and CoQ10 pretty well (19, 20). However, 
only clinical trials will be able to answer which CoQ10 
dose and timing provide the best protection against 
statin-related side effects in humans.
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Sažetak
Djelotvornost predtretmana štakorskih hepatocita koenzimom Q10 protiv toksičnosti statina
Statini su snažni lijekovi za snižavanje kolesterola, koji mogu izazvati ozbiljne nuspojave u mišićima i 
jetrima. Svrha je ovog in vitro istraživanja bila utvrditi zaštitno djelovanje koenzima Q10 (CoQ10, u optimalnoj 
dozi od 200 µmol L-1) protiv citotoksičnosti atorvastatina, simvastatina i lovastatina u izoliranih štakorskih 
hepatocita kroz parametre poput vijabilnosti, nastanka reaktivnih kisikovih čestica, lipidne peroksidacije, 
potencijala mitohondrijske membrane te reduciranog i oksidiranog glutationa. Rezultati su pokazali da 
predtretman štakorskih hepatocita CoQ10 djelotvorno ublažava toksične učinke statina te da bi njegovo 
kombiniranje sa statinima moglo zaštititi hepatocite (i druge vrste stanica) od oštećenja izazvanih statinima 
te ublažiti nuspojave povezane s ovim lijekovima.
KLJUČNE RIJEČI: atorvastatin; hepatotoksičnost; lipidna peroksidacija; lovastatin; oksidativni stres; 
reaktivne kisikove čestice; simvastatin; ubikvinon
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